U.S. FDA approves Cabenuva cabotegravir and rilpivirine for treatment of HIV

0
232
The United State's (U.S.) Food and Drug Administration (FDA) has approved Cabenuva cabotegravir and rilpivirine for every two months dosing for the treatment of HIV-1. This was disclosed by the U.S. HIV specialist pharmaceutical company ViiV Healthcare on Wednesday The treatment is for HIV in virologically suppressed adults on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. ViiV Healthcare is majority-owned by GlaxoSmithKline plc, with Pfizer and Shionogi Limited as shareholders. Cabenuva is the first and only complete long-acting HIV treatment regimen and was first approved by the U.S. FDA in January 2021 as a once-monthly treatment for HIV-1 in virologic ally suppressed adults. The U.S. FDA approval allows Cabenuva to be dosed monthly or every two months. Long-acting cabotegravir and rilpivirine are approved for use every two months in Canada under the name Cabenuva and in the EU as Vocabria and Rekambys.

The United State’s (U.S.) Food and Drug Administration (FDA) has approved Cabenuva cabotegravir and rilpivirine for every two months dosing for the treatment of HIV-1.

This was disclosed by the U.S. HIV specialist pharmaceutical company ViiV Healthcare on Wednesday

The treatment is for HIV in virologically suppressed adults on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.

ViiV Healthcare is majority-owned by GlaxoSmithKline plc, with Pfizer and Shionogi Limited as shareholders.

Cabenuva is the first and only complete long-acting HIV treatment regimen and was first approved by the U.S. FDA in January 2021 as a once-monthly treatment for HIV-1 in virologic ally suppressed adults.

The U.S. FDA approval allows Cabenuva to be dosed monthly or every two months.

Long-acting cabotegravir and rilpivirine are approved for use every two months in Canada under the name Cabenuva and in the EU as Vocabria and Rekambys.

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!